Incidentally Detected Malignancies in Lung Explants
Progress in Transplantation · 2022-12 · 32 (4) · 332-339
DOI: 10.1177/15269248221122876 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Progress in Transplantation, online erschienen am 07.09.2022. Verfasst von Deepika Razia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary and Lung Transplantation Division, Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Lung Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Introduction
Incidentally detected malignancies in lung explants portend risk of early cancer recurrence and metastases with posttransplant immunosuppression. We present a series of lung transplant recipients with previously unverified malignancies in native lung explants.
Design
We reviewed the histopathology, radiographic imaging, and management of lung explant malignancies at our institution over 10 years (2011-2020). Endpoints were survival and allograft rejection.
Results
An explant malignancy was found in 1.3% (11/855) of lung transplant recipients (6 [55%] men; median age 68 years; 6 [55%] ex-smokers [median pack-years, 25]). Nine (82%) were adenocarcinoma, 1 (9%) was squamous cell carcinoma (SCC), and 1 (9%) was follicular lymphoma. Three patients (27%) had multifocal involvement (≥3 lobes), 4 (36%) had nodal involvement, and the median (range) tumor size was 2.7 (0.4-19) cm. The median interval between last imaging and transplant was 58 (29-144) days. Mycophenolate mofetil was discontinued or reduced in all; everolimus was used in 2 patients, and cisplatin-pemetrexed chemotherapy was used in 2 patients. The prevalence of acute cellular rejection and chronic rejection was 27% and 9%, respectively. Lung recipients with cancer had significantly lower survival than those without (36.4% vs 67.3%, p = 0.002); median survival was 27 (17, 65) months in 4 recipients who were alive and cancer-free at the end of the study period.
Conclusions
Unidentified malignancies, commonly adenocarcinoma, can be detected in explanted native lungs. Pneumonectomy may be curative in SCC, lymphoproliferative disorders, and stage I adenocarcinoma. Modulating immunosuppression to prevent allograft rejection and tumor proliferation is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary and Lung Transplantation Division, Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
- Creighton University School of Medicine- Phoenix Campus, Phoenix, Arizona, USA.
- Radiology Division, Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
- Pathology Division, Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
- Thoracic Surgery and Lung Transplantation Division, Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
ORCID-Profile: Ross M Bremner, Rajat Walia
Zitieren
APA
Razia, D., Arjuna, A., Trahan, A., Hahn, M. F., Abdelrazek, H., Omar, A., Tokman, S., Hashimi, A. S., Huang, J., Smith, M. A., Bremner, R. M., & Walia, R. (2022). Incidentally Detected Malignancies in Lung Explants. Progress in Transplantation, 32(4), 332-339. https://doi.org/10.1177/15269248221122876
Vancouver
Razia D, Arjuna A, Trahan A, Hahn MF, Abdelrazek H, Omar A, et al. Incidentally Detected Malignancies in Lung Explants. Progress in Transplantation. 2022;32(4):332-339. doi:10.1177/15269248221122876
BibTeX
@article{Razia2022,
author = {Razia, Deepika and Arjuna, Ashwini and Trahan, Amy and Hahn, Mary F and Abdelrazek, Hesham and Omar, Ashraf and Tokman, Sofya and Hashimi, Abdul Samad and Huang, Jasmine and Smith, Michael A and Bremner, Ross M and Walia, Rajat},
title = {Incidentally Detected Malignancies in Lung Explants},
journal = {Progress in Transplantation},
year = {2022},
volume = {32},
number = {4},
pages = {332--339},
doi = {10.1177/15269248221122876}
}
EUVIMED